"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.
D000328:Adult; D002230:Carbidopa / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000097:blood / Q000627:therapeutic use; D004357:Drug Synergism; D005069:Evaluation Studies as Topic; D005260:Female; D006719:Homovanillic Acid / Q000097:blood; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007273:Injections, Intramuscular; D008297:Male; D008750:Methyldopa / Q000097:blood; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy*; D011736:Pyridoxine / Q000008:administration & dosage / Q000627:therapeutic use*
D006834:Hydrazines; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D011736:Pyridoxine; D002230:Carbidopa; D006719:Homovanillic Acid